ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,050 GBX | -0.87% |
|
+0.52% | +13.68% |
| May. 06 | Cellectis: alliance with AstraZeneca finalized | CF |
| May. 06 | Cellectis Secures $140 Million Additional Equity Investment From AstraZeneca | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.2
USD
Average target price
163.6
USD
Spread / Average Target
+8.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.68% | 234B | |
| +31.52% | 662B | |
| +21.96% | 546B | |
| -5.21% | 359B | |
| +17.02% | 323B | |
| +5.01% | 289B | |
| +3.81% | 198B | |
| -10.63% | 194B | |
| +3.98% | 167B | |
| -2.19% | 157B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca : Daiichi Sankyo, AstraZeneca's Late-Stage Trial of Enhertu for Gastric Cancer Doses First Patient